Multimodal Analysis of Early Biomarkers of the Impacts of Perinatal Asphyxia
NCT: NCT07702500 · NOT_YET_RECRUITING
Brief Summary
Current diagnostic methods rely primarily on clinical symptoms, supplemented by brain imaging and physiological tests. However, these signs of injury only become apparent once significant damage has occurred, thus delaying intervention and compromising the effectiveness of treatments. Therefore, there is a need to develop new markers to develop preventive measures for the consequences of perinatal asphyxia. The primary objective is to compare cognitive and motor development at 18 months in three populations (PA, at risk of PA, and Control) defined on the basis of clinical, biological, and neural criteria.
Frequently Asked Questions
What is Multimodal Analysis of Early Biomarkers of the Impacts of Perinatal Asphyxia?
Multimodal Analysis of Early Biomarkers of the Impacts of Perinatal Asphyxia is a clinical trial registered under NCT07702500. Current status: NOT_YET_RECRUITING.
What is the status of NCT07702500?
The current status of NCT07702500 (Multimodal Analysis of Early Biomarkers of the Impacts of Perinatal Asphyxia) is: NOT_YET_RECRUITING.
When did Multimodal Analysis of Early Biomarkers of the Impacts of Perinatal Asphyxia start?
Multimodal Analysis of Early Biomarkers of the Impacts of Perinatal Asphyxia started on 2026-07.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.